AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes

AstraZeneca ( (GB:AZN) ) has shared an announcement.

AstraZeneca has confirmed that as of 31 March 2026 its issued share capital with voting rights stands at 1,550,980,823 ordinary shares, with no shares held in treasury, establishing the total number of voting rights available to shareholders. This figure will serve as the reference denominator for investors assessing whether they must disclose holdings or changes under U.K. Financial Conduct Authority transparency rules.

The company also reported the admission to trading on the London Stock Exchange of 491 additional ordinary shares, issued between 20 and 31 March 2026 under existing employee share schemes. These new shares, fully fungible with existing stock and admitted under a prior block admission, slightly increase the overall share count and reflect ongoing use of equity-based compensation without materially altering AstraZeneca’s capital structure.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing and commercialising prescription medicines across Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, U.K., its medicines are sold in more than 125 countries and used by millions of patients worldwide.

For an in-depth examination of AZN stock, go to TipRanks’ Overview page.